Lilly says new diabetes drug outperforms Ozempic in major study

Eli Lilly said its investigational drug retatrutide was more effective at lowering blood sugar and reducing weight than Novo Nordisk’s Ozempic in a large diabetes study, according to STAT. The announcement positions Lilly as a strong competitor in the diabetes treatment market.

For pharma executives, this signals a shift in the competitive field for diabetes therapies. The result could influence future regulatory reviews, payer decisions and market share in a major therapeutic area.